MSMarius Schwerg

Marius Schwerg

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marius Schwerg has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Christoph Melzer

    Herzschrittmacher- und ICD-Zentrum Berlin, Berlin, Germany

    4 shared publications
  • Henryk Dreger

    Department of Cardiology and Angiology, Campus Mitte, Charité—Universitätsmedizin Berlin, Berlin, Germany

    3 shared publications
  • Hansjürgen Bondke

    Department of Cardiology and Angiology Charité – Universitätsmedizin Berlin Germany

    2 shared publications
  • Karl Stangl

    Department of Cardiology and Angiology, Campus Mitte, Charité—Universitätsmedizin Berlin, Berlin, Germany

    2 shared publications
  • Michael Laule

    Department of Cardiology, Charité — Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, Germany

    2 shared publications
  • Wolfram C. Poller

    Center for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

    2 shared publications

Latest Publications

  • Open Access

    Prevalence of left ventricular systolic dysfunction in a typical outpatient pacemaker cohort

    by Marius Schwerg, Henryk Dreger, Karl Stangl, Volker Leonhardt, Christoph Melzer

    Background: Right ventricular (RV) pacing is the standard treatment for symptomatic bradycardia. RV pacing is known to cause dyssyncrony. New treatment options like His bundle pacing enhance the focus on left ventricular dysfunction in patients with pacemakers. Objectives: The aim of this cross-sectional study was to obtain a real-life picture of the patients in a representative cohort of outpatients with permanent pacemakers. The prevalence and causes of left ventricular dysfunction (LVD) were explored. Methods: In total, 1869 patients of a pacemaker outpatient clinic were screened for left ventricular systolic dysfunction by transthoracic echocardiography. All patients were interviewed for symptoms and cardiologist care. Percentages of RV pacing and underlying cardiac disease were recorded. Results: A left ventricular ejection fraction (LVEF) under 45% was found in 207 (11.1%) of all patients. Predictive factors for a reduced LVEF were a high pacing rate and long-term pacing. LVD due to RV pacing was diagnosed in 3.4% of all patients. Only 845 patients (45%) reported that they regularly visited a cardiologist. Conclusion: There is a high prevalence of unknown LVD in a typical pacemaker cohort. Therefore, regular echocardiographic examinations should be performed in outpatients of pacemaker clinics.


  • Open Access

    Valve in valve implantation of the CoreValve Evolut R in degenerated surgical aortic valves

    by Marius Schwerg, Karl Stangl, Michael Laule, Verena Stangl, Henryk Dreger

    Background: The new CoreValve Evolut R has an improved design to minimize paravalvular leakage (PVL) and allows repositioning of the valve. For patients with degenerated bioprosthetic aortic valves, transcatheter aortic valve implantation (TAVI) represents a less invasive option. Herein reported are valve-in-valve (ViV) implantations of this new valve. Methods: A total of 26 patients (mean age 79.4 ± 6.1 years, 17 males and 9 females) were treated for severe prosthesis stenosis (n = 9), severe regurgitation (n = 8) or severe combination of stenosis and regurgitation (n = 9). All patients underwent transthoracic echocardiography before and after ViV implantation. Results: ViV implantation of a CoreValve Evolut R was performed successfully in all patients. The mean transaortic gradient for stenotic valves determined by transthoracic echocardiography was reduced significantly from 37.5 ± 15.3 mmHg in patients with prosthesis stenosis to 16.3 ± 8.2 mmHg (p < 0.001). In all cases with severe prosthesis regurgitation, regurgitation was reduced to none or mild. All-cause mortality after 30 days was 0%. Conclusions: It was concluded that CoreValve Evolut R is well suited for ViV implantation. Background: The new CoreValve Evolut R has an improved design to minimize paravalvular leakage (PVL) and allows repositioning of the valve. For patients with degenerated bioprosthetic aortic valves, transcatheter aortic valve implantation (TAVI) represents a less invasive option. Herein reported are valve-in-valve (ViV) implantations of this new valve. Methods: A total of 26 patients (mean age 79.4 ± 6.1 years, 17 males and 9 females) were treated for severe prosthesis stenosis (n = 9), severe regurgitation (n = 8) or severe combination of stenosis and regurgitation (n = 9). All patients underwent transthoracic echocardiography before and after ViV implantation. Results: ViV implantation of a CoreValve Evolut R was performed successfully in all patients. The mean transaortic gradient for stenotic valves determined by transthoracic echocardiography was reduced significantly from 37.5 ± 15.3 mmHg in patients with prosthesis stenosis to 16.3 ± 8.2 mmHg (p < 0.001). In all cases with severe prosthesis regurgitation, regurgitation was reduced to none or mild. All-cause mortality after 30 days was 0%. Conclusions: It was concluded that CoreValve Evolut R is well suited for ViV implantation.


  • Efficacy of optimal medical therapy and cardiac resynchronization therapy upgrade in patients with pacemaker-induced cardiomyopathy

    by Marius Schwerg, Henryk Dreger, Wolfram C. Poller, Benjamin Dust, Christoph Melzer

    The aim of our study was to assess the prevalence of pacemaker-induced cardiomyopathy (PMiCMP) and its response to biventricular stimulation and optimal medical therapy. To identify patients with PMiCMP, we screened all patients that presented for pacemaker interrogation in our outpatient clinic in 2012 and 2013 (n = 615). Left ventricular (LV) function was assessed by transthoracic echocardiography. PMiCMP was defined as deterioration of left ventricular ejection fraction (LVEF) P < 0.001) within 6 months. Positive response to CRT was observed in 17 patients (85 %). In the group without device upgrade, LVEF was 40.5 ± 5 % and did not change during the follow-up period of 1 year. Optimal medical therapy lacks efficacy in PMiCMP patients. The response rate to CRT was significantly higher in PMiCMP patients compared to average CRT patients.


  • Clinical, Anatomical, and Technical Risk Factors for Postoperative Pacemaker or Defibrillator Lead Perforation with Particular Focus on Myocardial Thickness

    by Marius Schwerg, Martin Stockburger, Christoph Schulze, Hansjürgen Bondke, Wolfram C. Poller, Alexander Lembcke, Christoph Melzer

    Background: Postoperative lead perforation is a life‐threatening complication of cardiac pacing. Identification of precipitating factors for this serious complication may help to anticipate a specific risk profile and to minimize the incidence.Methods: We conducted a retrospective tertiary referral center analysis to clarify clinical, anatomical, and technical characteristics related to pacemaker (PM) and cardioverter/defibrillator lead perforation.We examined the baseline characteristics and the symptoms. In a subgroup, we investigated the myocardial thickness on contrast‐enhanced cardiac computed tomography.Results: We enrolled 26 patients. Female gender appears to put patients at slightly increased risk for lead perforation. In a majority active fixation leads were used. Symptoms occurred in 72%. Pericardial effusion and tamponade were present in 38% and 19%, respectively. Sensing was compromised in 65%. A high pacing threshold or exit block occurred in 92%. Myocardial thickness did not differ between patients with or without perforation. In 96%, the perforation was treated by transvenous withdrawal.Conclusion: Chest pain, phrenic stimulation, bad sensing, or exit block early after PM implantation must prompt radiological and echocardiographic evaluation. A missing pericardial effusion particularly late after implantation does not rule out a perforation. Especially active fixating leads have a higher risk of perforation. With cardiac surgery in standby transvenous withdrawal is a safe way to treat lead perforation.


  • Complete Atrioventricular Block after TAVI: When Is Pacemaker Implantation Safe?

    by Marius Schwerg, Gerd Baldenhofer, Henryk Dreger, Hansjürgen Bondke, Karl Stangl, Michael Laule, Christoph Melzer

    Introduction Atrioventricular (AV) block is a frequent complication of transcatheter aortic valve implantation (TAVI). TAVI is routinely performed under anticoagulation using heparin, which potentially may lead to an increased bleeding rate in patients who undergo permanent pacemaker (PPM) implantation immediately after TAVI. As the number of TAVI procedures continues to rise, data on the optimal management of TAVI-related AV block are needed. Therefore, the aim of our study was to analyze PPM implantation-related complications after TAVI. Methods We retrospectively collected data on PPM implantations after TAVI in our center from January 2010 to December 2012. In total, we included 30 patients who received a PPM for TAVI-related AV block. Twelve patients (group A) underwent PPM implantation on the day of TAVI. In 18 patients (group B), PPM implantation was performed at least 1 day after TAVI (3.8 ± 4.5 days). Since all patients undergoing TAVI receive dual antiplatelet therapy (DA-therapy), we compared all implantations after TAVI with a historic patient cohort that underwent PPM implantation under DA-therapy. Results Procedure times, fluid loss via drainage systems, and drainage times were neither significantly different between groups A and B nor between all PPM implantations after TAVI compared to the historic control group. Conclusion PPM implantation immediately after TAVI is safe and can be performed without increased rate of complications.